PTG standards for the use of progesterone for prevention of the preterm birth Review article
Article Sidebar
Published:
Dec 31, 2013
Keywords:
preterm delivery, progesterone, cervical cerclage
Main Article Content
Abstract
Preterm birth remains a major contributor to perinatal death worldwide and the second most common cause-of-death in children younger than 5 years after pneumonia. Unfortunatelly there are only few prophylactic therapies that are available and they do not work for all women. The most important strategies in prophylactics are: progesterone and cervical cerclage, which are effective in selected women with singleton pregnancy.
Article Details
How to Cite
Błażejewska, A. (2013). PTG standards for the use of progesterone for prevention of the preterm birth. Medycyna Faktow (J EBM), 6(4(21), 30-33. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2393
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Niepłodność i rozród wspomagany. Radwan J., Wołczyński S. (red.). Termedia Wydawnictwa Medyczne, Poznań 2011: 313.
2. Speroff L., Glass G., Kase N.: Ectopic pregnancy. Clinical Gynecologic Endocrinology and Infertility. Wiliams and Wilkins, Maryland, Baltimore 1994.
3. Szeraday L., Varga P., Szekeres-Bartho J.: Cytokine production in pregnancy. Am. J. Reprod. Immunol. 1997; 38: 418-422.
4. Wahabi H., Fayed A.A., Esmaeil S.A. et al.: Progestogen for treating threatened miscarriage. Cochrane Database Syst. Rev. 2011; CD005943.
5. Rekomendacje PTG dotyczące stosowania progesteronu w ginekologii i położnictwie. Ginekol. Pol. 2012; 83: 76-79.
6. Sachez-Ramos L., Kaunitz A.M., Delke I.: Progestational agents to prevent preterm birth: a meta-analysis of randomized controlled trials. Obstet. Gynecol. 2005; 105: 273.
7. Dodd J., Flenady V., Cincotta R., Crowther C.: Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth. Cochrane Database Syst. Rev. 2006; CD004947.
8. Hassan S., Romero R., Vidyadhari D. et al.: Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet. Gynecol. 2011; 38: 8-31.
9. Su L., Samuel M., Chong Y.: Progestational agents for treating threatened or established preterm labour. Cochrane Database Syst. Rev. 2010; CD006770.
10. Fonseca E.B., Celik E., Parra M. et al.: Progesterone and the risk of preterm birth among women with a short cervix. N. Engl. J. Med. 2007; 357(5): 462.
11. Keeler S., Kiefer D., Rochon M. et al.: A randomized trial of cerclage vs. 17-alpha-hydroxyprogesterone caproate for treatment of short cervix. J. Perinat. Med. 2009; 37: 473.
12. Norman J.E., Mackenzie F., Owen P. et al.: Progesterone for prevention of preterm birth in twin pregnancy (STOPPIT): a randomized, doubleblind, placebo-controlled study and meta-analysis. Lancet 2009; 373(9680): 2034.
13. Caritis S.N., Rouse D.J., Peaceman A.M. et al.: Prevention of preterm birth in triplets using 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial. Obstet. Gynecol. 2009; 113: 285.
14. Rebarber A., Istwan N.B., Russo-Stieglitz K. et al.: Increased incidence of gestational diabetes in women receiving prophylactic 17 alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery. Diabetes Care 2007; 30(9): 2277.
15. Northen A.T., Norman G.S., Anderson K. et al.: Follow-up of children exposed in utero to 17 alpha-hydroxyprogesterone caproate compared with placebo. Obstet. Gynecol. 2007; 110: 865.
16. Cicinelli E.: Intravaginal oestrogen and progestin administration: advantages and disadvantages. Best Pract. Res. Clin. Obstet. Gynaecol. 2008; 22: 391-405.
17. How H.Y., Sibai B.M.: Progesterone for the prevention of preterm birth: indications, when to initiate, efficacy and safety. Ther. Clin. Risk. Manag. 2009; 5: 55-64.
18. Haas D., Ramsey P.: Progestogen for preventing miscarriage. Cochrane Database Syst. Rev. 2008; CD003511.
19. Bręborowicz G.H.: Poród przedwczesny. Ciąża wysokiego ryzyka. Ośrodek Wydawnictw Naukowych, Poznań 2010.
2. Speroff L., Glass G., Kase N.: Ectopic pregnancy. Clinical Gynecologic Endocrinology and Infertility. Wiliams and Wilkins, Maryland, Baltimore 1994.
3. Szeraday L., Varga P., Szekeres-Bartho J.: Cytokine production in pregnancy. Am. J. Reprod. Immunol. 1997; 38: 418-422.
4. Wahabi H., Fayed A.A., Esmaeil S.A. et al.: Progestogen for treating threatened miscarriage. Cochrane Database Syst. Rev. 2011; CD005943.
5. Rekomendacje PTG dotyczące stosowania progesteronu w ginekologii i położnictwie. Ginekol. Pol. 2012; 83: 76-79.
6. Sachez-Ramos L., Kaunitz A.M., Delke I.: Progestational agents to prevent preterm birth: a meta-analysis of randomized controlled trials. Obstet. Gynecol. 2005; 105: 273.
7. Dodd J., Flenady V., Cincotta R., Crowther C.: Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth. Cochrane Database Syst. Rev. 2006; CD004947.
8. Hassan S., Romero R., Vidyadhari D. et al.: Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet. Gynecol. 2011; 38: 8-31.
9. Su L., Samuel M., Chong Y.: Progestational agents for treating threatened or established preterm labour. Cochrane Database Syst. Rev. 2010; CD006770.
10. Fonseca E.B., Celik E., Parra M. et al.: Progesterone and the risk of preterm birth among women with a short cervix. N. Engl. J. Med. 2007; 357(5): 462.
11. Keeler S., Kiefer D., Rochon M. et al.: A randomized trial of cerclage vs. 17-alpha-hydroxyprogesterone caproate for treatment of short cervix. J. Perinat. Med. 2009; 37: 473.
12. Norman J.E., Mackenzie F., Owen P. et al.: Progesterone for prevention of preterm birth in twin pregnancy (STOPPIT): a randomized, doubleblind, placebo-controlled study and meta-analysis. Lancet 2009; 373(9680): 2034.
13. Caritis S.N., Rouse D.J., Peaceman A.M. et al.: Prevention of preterm birth in triplets using 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial. Obstet. Gynecol. 2009; 113: 285.
14. Rebarber A., Istwan N.B., Russo-Stieglitz K. et al.: Increased incidence of gestational diabetes in women receiving prophylactic 17 alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery. Diabetes Care 2007; 30(9): 2277.
15. Northen A.T., Norman G.S., Anderson K. et al.: Follow-up of children exposed in utero to 17 alpha-hydroxyprogesterone caproate compared with placebo. Obstet. Gynecol. 2007; 110: 865.
16. Cicinelli E.: Intravaginal oestrogen and progestin administration: advantages and disadvantages. Best Pract. Res. Clin. Obstet. Gynaecol. 2008; 22: 391-405.
17. How H.Y., Sibai B.M.: Progesterone for the prevention of preterm birth: indications, when to initiate, efficacy and safety. Ther. Clin. Risk. Manag. 2009; 5: 55-64.
18. Haas D., Ramsey P.: Progestogen for preventing miscarriage. Cochrane Database Syst. Rev. 2008; CD003511.
19. Bręborowicz G.H.: Poród przedwczesny. Ciąża wysokiego ryzyka. Ośrodek Wydawnictw Naukowych, Poznań 2010.